XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $1.05M invested in XTL Biopharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
20% less capital invested
Capital invested by funds: $1.31M → $1.05M (-$261K)
33% less funds holding
Funds holding: 6 → 4 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$64K |
| 2 |
Morgan Stanley
New York
|
-$4.42K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NC
1
Noked Capital
Tel Aviv,
Israel
| $471K | – | – | – |
|
|
NI
2
Noked Israel
Ramat Hasharon,
Israel
| $471K | – | – | – |
|
|
3
Morgan Stanley
New York
| $102K | -$4.42K | -450 | -4% |
|
|
4
UBS Group
Zurich,
Switzerland
| $2K | +$1.61K | +164 | +421% |
|
|
5
Renaissance Technologies
New York
| – | -$64K | -5,820 | Closed |
|
XTLB Hedge Fund Activity: Q1 2022 in Review
4 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2022, worth a combined $1.05M — down 20% from $1.31M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of XTLB and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $1.61K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $64K sold.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2022, down from 6 in Q4 2021.
- Funds reported $1.05M of XTL Biopharmaceuticals stock for Q1 2022, down 20% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q1 2022 and 2 closed out, a net change of -2 holders.
- The largest XTL Biopharmaceuticals buyer in Q1 2022 was UBS Group, an estimated $1.61K added.
- The largest XTL Biopharmaceuticals seller in Q1 2022 was Renaissance Technologies, an estimated $64K sold.
Based on aggregated 13F filings for Q1 2022.